SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax)(SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax))

概要

基本信息

药物类型

预防性疫苗、多价疫苗

别名

CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant、CIC vaccine contains SARs-CoV-2 antigen, tNIV antigens (2 influenza A [H1N1 and H3N2] and influenza B-Victoria lineage strains、COVID-19 and Influenza Combination Vaccine

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染流感病毒感染

非在研适应症-

原研机构

Novavax, Inc.

在研机构

Novavax, Inc.

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的临床试验

NCT06482359

/ Withdrawn临床2/3期

A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 65 Years of Age

The goal of Phase 3 Study is Comparing the Safety and Immune Response of Three Batches of a COVID-19 and Flu Combination Vaccine in Seniors Aged 65+

开始日期2025-02-01

申办/合作机构

Novavax, Inc.

NCT06291857

/ Active, not recruiting临床3期

A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ≥ 65 Years of Age.

This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won't know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It's a large-scale, final-stage study designed to thoroughly check how well the vaccines trigger an immune response (immunogenicity) and how safe they are.

开始日期2024-12-09

申办/合作机构

Novavax, Inc.

100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的临床结果

登录后查看更多信息

100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的转化医学

登录后查看更多信息

100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的专利（医药）

登录后查看更多信息

100 项与 SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine(Novavax) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	澳大利亚	Novavax, Inc.	2024-12-09
新型冠状病毒感染	临床3期	新西兰	Novavax, Inc.	2024-12-09
流感病毒感染	临床3期	澳大利亚	Novavax, Inc.	2024-12-09
流感病毒感染	临床3期	新西兰	Novavax, Inc.	2024-12-09